| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 7 | 2025 | 235 | 2.970 |
Why?
|
| Mitochondria | 13 | 2025 | 692 | 2.670 |
Why?
|
| src-Family Kinases | 2 | 2025 | 90 | 1.410 |
Why?
|
| Fatty Acids | 9 | 2025 | 351 | 1.380 |
Why?
|
| Cell Line, Tumor | 24 | 2025 | 3342 | 1.010 |
Why?
|
| Breast Neoplasms | 13 | 2024 | 2513 | 0.960 |
Why?
|
| Biguanides | 1 | 2025 | 14 | 0.960 |
Why?
|
| Antineoplastic Agents | 5 | 2025 | 1668 | 0.810 |
Why?
|
| DNA, Mitochondrial | 4 | 2014 | 211 | 0.810 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 292 | 0.800 |
Why?
|
| Neoplasms | 7 | 2025 | 2789 | 0.800 |
Why?
|
| Signal Transduction | 7 | 2025 | 4543 | 0.780 |
Why?
|
| NF-kappa B | 1 | 2024 | 457 | 0.750 |
Why?
|
| Energy Metabolism | 4 | 2025 | 778 | 0.710 |
Why?
|
| CD24 Antigen | 3 | 2024 | 29 | 0.560 |
Why?
|
| Glycolysis | 5 | 2025 | 149 | 0.550 |
Why?
|
| Oxidative Phosphorylation | 6 | 2025 | 108 | 0.530 |
Why?
|
| Honey | 2 | 2002 | 3 | 0.410 |
Why?
|
| Animals | 28 | 2025 | 34195 | 0.410 |
Why?
|
| Cell Fusion | 1 | 2012 | 38 | 0.390 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2025 | 171 | 0.390 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 247 | 0.380 |
Why?
|
| Luminescent Agents | 3 | 2016 | 7 | 0.360 |
Why?
|
| Europium | 3 | 2016 | 6 | 0.360 |
Why?
|
| Cell Nucleus | 1 | 2013 | 677 | 0.350 |
Why?
|
| Humans | 54 | 2025 | 124822 | 0.350 |
Why?
|
| Phosphorylation | 4 | 2024 | 1626 | 0.320 |
Why?
|
| Mice | 16 | 2025 | 17747 | 0.320 |
Why?
|
| Cell Proliferation | 7 | 2025 | 2307 | 0.320 |
Why?
|
| Crohn Disease | 2 | 2023 | 284 | 0.320 |
Why?
|
| Wnt1 Protein | 1 | 2009 | 71 | 0.310 |
Why?
|
| Egg White | 1 | 2008 | 10 | 0.310 |
Why?
|
| Mice, Nude | 2 | 2025 | 711 | 0.310 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2001 | 32 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2025 | 1900 | 0.300 |
Why?
|
| Mutation | 6 | 2025 | 5815 | 0.270 |
Why?
|
| PPAR alpha | 2 | 2024 | 54 | 0.270 |
Why?
|
| Glucose | 4 | 2025 | 885 | 0.270 |
Why?
|
| Heterozygote | 1 | 2009 | 676 | 0.270 |
Why?
|
| Estrogens | 2 | 2009 | 515 | 0.270 |
Why?
|
| Glutamine | 2 | 2025 | 215 | 0.270 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 557 | 0.260 |
Why?
|
| Nanotubes | 2 | 2016 | 13 | 0.250 |
Why?
|
| Muscle, Skeletal | 2 | 2025 | 953 | 0.250 |
Why?
|
| Polymorphism, Genetic | 5 | 2005 | 810 | 0.250 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 2060 | 0.250 |
Why?
|
| Electron Transport Complex I | 2 | 2024 | 32 | 0.250 |
Why?
|
| Food-Drug Interactions | 2 | 2002 | 10 | 0.250 |
Why?
|
| DNA Repair | 3 | 2022 | 587 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 888 | 0.250 |
Why?
|
| Transcriptome | 3 | 2025 | 940 | 0.240 |
Why?
|
| Carcinogenesis | 2 | 2019 | 333 | 0.240 |
Why?
|
| Dasatinib | 1 | 2025 | 40 | 0.240 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2024 | 4 | 0.240 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2025 | 189 | 0.230 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 577 | 0.230 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2024 | 6 | 0.230 |
Why?
|
| Glutaminase | 1 | 2024 | 16 | 0.230 |
Why?
|
| Oncolytic Viruses | 1 | 2025 | 72 | 0.230 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2025 | 76 | 0.230 |
Why?
|
| Female | 24 | 2025 | 66580 | 0.230 |
Why?
|
| Oncolytic Virotherapy | 1 | 2025 | 84 | 0.220 |
Why?
|
| Ileitis | 1 | 2023 | 10 | 0.220 |
Why?
|
| Adenosine Triphosphate | 4 | 2022 | 284 | 0.220 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 153 | 0.220 |
Why?
|
| DNA Damage | 2 | 2017 | 516 | 0.210 |
Why?
|
| Carcinogens | 2 | 2017 | 153 | 0.210 |
Why?
|
| Metformin | 1 | 2025 | 150 | 0.210 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 237 | 0.210 |
Why?
|
| Diltiazem | 1 | 2002 | 13 | 0.210 |
Why?
|
| Adipogenesis | 1 | 2023 | 77 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 550 | 0.200 |
Why?
|
| Cells, Cultured | 1 | 2008 | 3061 | 0.200 |
Why?
|
| Carbamazepine | 1 | 2002 | 48 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 670 | 0.200 |
Why?
|
| Life Style | 1 | 2025 | 414 | 0.190 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2021 | 48 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2021 | 62 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 724 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 4 | 2008 | 1588 | 0.180 |
Why?
|
| Stomach Ulcer | 4 | 2001 | 92 | 0.180 |
Why?
|
| Ataxia Telangiectasia | 1 | 2021 | 15 | 0.180 |
Why?
|
| Hypogonadism | 1 | 2025 | 284 | 0.180 |
Why?
|
| Mutant Proteins | 2 | 2019 | 112 | 0.180 |
Why?
|
| Duodenal Ulcer | 4 | 2001 | 127 | 0.180 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 431 | 0.180 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2021 | 28 | 0.180 |
Why?
|
| Obesity | 2 | 2025 | 2279 | 0.180 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1473 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 95 | 0.180 |
Why?
|
| Mice, SCID | 3 | 2016 | 571 | 0.170 |
Why?
|
| Autophagy | 2 | 2016 | 395 | 0.170 |
Why?
|
| Glioma | 1 | 2025 | 497 | 0.170 |
Why?
|
| Computational Biology | 1 | 2025 | 821 | 0.170 |
Why?
|
| Oxidation-Reduction | 2 | 2023 | 443 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 1291 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 215 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 300 | 0.170 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2019 | 29 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 198 | 0.160 |
Why?
|
| Testosterone | 1 | 2025 | 538 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 428 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 721 | 0.160 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 492 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 211 | 0.160 |
Why?
|
| Estrogen Receptor beta | 1 | 2019 | 79 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 313 | 0.160 |
Why?
|
| Anticonvulsants | 1 | 2002 | 381 | 0.160 |
Why?
|
| Resistance Training | 1 | 2019 | 32 | 0.160 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 37 | 0.160 |
Why?
|
| Osteosarcoma | 1 | 2021 | 259 | 0.160 |
Why?
|
| India | 5 | 2005 | 219 | 0.160 |
Why?
|
| Antioxidants | 1 | 2021 | 336 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 96 | 0.150 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 277 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 561 | 0.150 |
Why?
|
| Optical Imaging | 2 | 2016 | 66 | 0.150 |
Why?
|
| Gastric Acid | 4 | 2001 | 50 | 0.150 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2018 | 14 | 0.150 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2018 | 28 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 399 | 0.150 |
Why?
|
| Response Elements | 1 | 2018 | 97 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 260 | 0.140 |
Why?
|
| Inflammation | 2 | 2023 | 1428 | 0.140 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2018 | 52 | 0.140 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 31 | 0.140 |
Why?
|
| Endoribonucleases | 1 | 2018 | 82 | 0.140 |
Why?
|
| Models, Biological | 4 | 2025 | 1461 | 0.140 |
Why?
|
| Mutagens | 1 | 2017 | 84 | 0.140 |
Why?
|
| Tobacco Products | 1 | 2017 | 61 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 187 | 0.130 |
Why?
|
| Hexosamines | 1 | 2016 | 16 | 0.130 |
Why?
|
| Nanotechnology | 1 | 2016 | 49 | 0.130 |
Why?
|
| Cell Survival | 3 | 2013 | 807 | 0.130 |
Why?
|
| Chloroquine | 1 | 2016 | 32 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2019 | 418 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 693 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1241 | 0.130 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 791 | 0.130 |
Why?
|
| Gadolinium | 1 | 2016 | 104 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 183 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 2 | 2010 | 468 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 376 | 0.120 |
Why?
|
| Molecular Imaging | 2 | 2015 | 61 | 0.120 |
Why?
|
| Cell Line | 3 | 2019 | 2770 | 0.120 |
Why?
|
| Graphite | 2 | 2012 | 9 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 375 | 0.120 |
Why?
|
| Prostate | 1 | 2018 | 435 | 0.120 |
Why?
|
| Apoptosis | 3 | 2017 | 1792 | 0.120 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 88 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 60 | 0.120 |
Why?
|
| Mixed Function Oxygenases | 1 | 2005 | 30 | 0.120 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 43 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2005 | 66 | 0.120 |
Why?
|
| Tissue Fixation | 1 | 2005 | 38 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 415 | 0.120 |
Why?
|
| Phosphates | 1 | 2015 | 115 | 0.120 |
Why?
|
| HeLa Cells | 2 | 2021 | 809 | 0.120 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 123 | 0.110 |
Why?
|
| DNA | 2 | 2022 | 1604 | 0.110 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 395 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2010 | 795 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 1341 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 356 | 0.110 |
Why?
|
| Drug Design | 1 | 2015 | 147 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 4615 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2017 | 1004 | 0.110 |
Why?
|
| Hybrid Cells | 1 | 2013 | 80 | 0.110 |
Why?
|
| Exercise | 1 | 2019 | 820 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 96 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2005 | 421 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 796 | 0.100 |
Why?
|
| Yttrium | 1 | 2012 | 4 | 0.100 |
Why?
|
| Heterografts | 1 | 2013 | 178 | 0.100 |
Why?
|
| Paneth Cells | 2 | 2023 | 23 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 411 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1019 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 128 | 0.100 |
Why?
|
| Half-Life | 2 | 2002 | 158 | 0.100 |
Why?
|
| Ethidium | 1 | 2012 | 8 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2012 | 42 | 0.100 |
Why?
|
| Uridine | 1 | 2012 | 34 | 0.100 |
Why?
|
| Quantum Dots | 1 | 2012 | 12 | 0.100 |
Why?
|
| Vasotocin | 2 | 2001 | 2 | 0.100 |
Why?
|
| Nanostructures | 1 | 2012 | 52 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 1044 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2013 | 298 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2002 | 320 | 0.090 |
Why?
|
| Carbon | 1 | 2012 | 91 | 0.090 |
Why?
|
| Rabbits | 2 | 2002 | 712 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2009 | 238 | 0.090 |
Why?
|
| Phenotype | 5 | 2025 | 4260 | 0.090 |
Why?
|
| Oxytocin | 2 | 2001 | 69 | 0.090 |
Why?
|
| Rats | 6 | 2024 | 3693 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 2 | 2001 | 110 | 0.090 |
Why?
|
| Gene Frequency | 3 | 2005 | 720 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 606 | 0.080 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2009 | 24 | 0.080 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2009 | 19 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 618 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 2626 | 0.080 |
Why?
|
| Transfection | 1 | 2012 | 1069 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3589 | 0.080 |
Why?
|
| Male | 13 | 2025 | 61314 | 0.080 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2009 | 57 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 1549 | 0.080 |
Why?
|
| Immunity | 1 | 2009 | 189 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 49 | 0.080 |
Why?
|
| Egg Proteins | 1 | 2008 | 55 | 0.080 |
Why?
|
| Contrast Media | 1 | 2012 | 471 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 56 | 0.080 |
Why?
|
| Laminin | 1 | 2008 | 70 | 0.070 |
Why?
|
| Nanoparticles | 2 | 2024 | 236 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2008 | 92 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 214 | 0.070 |
Why?
|
| Risk | 1 | 2010 | 757 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 75 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1491 | 0.070 |
Why?
|
| Metabolomics | 2 | 2024 | 419 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2008 | 267 | 0.070 |
Why?
|
| Genetics, Population | 2 | 2005 | 187 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 339 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3753 | 0.070 |
Why?
|
| Collagen | 1 | 2008 | 316 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2825 | 0.070 |
Why?
|
| Genotype | 3 | 2005 | 2557 | 0.070 |
Why?
|
| Anthracyclines | 2 | 2007 | 36 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2008 | 701 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 582 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 32 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2025 | 86 | 0.060 |
Why?
|
| Luminescent Measurements | 2 | 2016 | 57 | 0.060 |
Why?
|
| Prolactin | 2 | 2001 | 114 | 0.060 |
Why?
|
| Iron | 2 | 2023 | 268 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2016 | 178 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 339 | 0.060 |
Why?
|
| Adult | 7 | 2021 | 29484 | 0.060 |
Why?
|
| Dextromethorphan | 2 | 2001 | 11 | 0.050 |
Why?
|
| Butyrates | 1 | 2023 | 35 | 0.050 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2023 | 8 | 0.050 |
Why?
|
| Flavoproteins | 1 | 2023 | 17 | 0.050 |
Why?
|
| Ceramides | 1 | 2023 | 38 | 0.050 |
Why?
|
| Base Sequence | 3 | 2014 | 3100 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 488 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2036 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1704 | 0.050 |
Why?
|
| Bone Density | 1 | 2025 | 320 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2025 | 196 | 0.050 |
Why?
|
| Phosphofructokinase-1 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 644 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 24 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2022 | 47 | 0.050 |
Why?
|
| Fasting | 1 | 2023 | 303 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 85 | 0.050 |
Why?
|
| Hyperprolactinemia | 1 | 2001 | 23 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2001 | 84 | 0.050 |
Why?
|
| Tamoxifen | 2 | 2010 | 363 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 550 | 0.050 |
Why?
|
| Enterocytes | 1 | 2021 | 75 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2021 | 150 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 155 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2021 | 162 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2002 | 683 | 0.040 |
Why?
|
| Rats, Wistar | 4 | 2001 | 360 | 0.040 |
Why?
|
| Epithelium | 1 | 2021 | 362 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1692 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 205 | 0.040 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
| DNA Primers | 2 | 2011 | 660 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 195 | 0.040 |
Why?
|
| Aged | 4 | 2025 | 19697 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 6522 | 0.040 |
Why?
|
| Stomach | 1 | 2001 | 271 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 4786 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2019 | 80 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2021 | 334 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 26730 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 166 | 0.040 |
Why?
|
| Drosophila | 1 | 2023 | 781 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 145 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1237 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 780 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2005 | 1493 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 359 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 355 | 0.040 |
Why?
|
| Metribolone | 1 | 2018 | 29 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 62 | 0.040 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1068 | 0.040 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 11 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 19 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2017 | 19 | 0.040 |
Why?
|
| Acetic Acid | 3 | 2001 | 18 | 0.040 |
Why?
|
| Cysteamine | 3 | 2001 | 14 | 0.040 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2007 | 21 | 0.040 |
Why?
|
| Pylorus | 3 | 2001 | 21 | 0.040 |
Why?
|
| Azacitidine | 1 | 2017 | 53 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 1239 | 0.040 |
Why?
|
| Indomethacin | 3 | 2001 | 84 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2017 | 78 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2017 | 19 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 73 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2007 | 128 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1001 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3882 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 359 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 271 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 67 | 0.030 |
Why?
|
| Magnets | 1 | 2016 | 22 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 309 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 184 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 39 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 1699 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 50 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 356 | 0.030 |
Why?
|
| Carboplatin | 1 | 2016 | 77 | 0.030 |
Why?
|
| Liver | 1 | 2023 | 1764 | 0.030 |
Why?
|
| Androgens | 1 | 2018 | 275 | 0.030 |
Why?
|
| Superoxides | 1 | 2016 | 154 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 670 | 0.030 |
Why?
|
| Haplotypes | 1 | 2007 | 520 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 491 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 2005 | 8 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 228 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2005 | 3 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 868 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2005 | 19 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 33 | 0.030 |
Why?
|
| Methotrexate | 1 | 2007 | 341 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2018 | 426 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2005 | 35 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 294 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 143 | 0.030 |
Why?
|
| Breast Diseases | 1 | 2005 | 35 | 0.030 |
Why?
|
| Kidney | 1 | 2001 | 1353 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 80 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 130 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 303 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 356 | 0.030 |
Why?
|
| Telomerase | 1 | 2014 | 160 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1929 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2001 | 1192 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4356 | 0.030 |
Why?
|
| Chromatin | 1 | 2016 | 555 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 834 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 96 | 0.020 |
Why?
|
| Oxides | 1 | 2012 | 15 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 534 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 121 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 134 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 910 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 83 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 93 | 0.020 |
Why?
|
| Fluorescence | 1 | 2012 | 95 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 121 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 426 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1248 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 647 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 1499 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1691 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 670 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 38 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 82 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 575 | 0.020 |
Why?
|
| Ethanol | 2 | 2001 | 163 | 0.020 |
Why?
|
| Alleles | 1 | 2005 | 1619 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2010 | 212 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1042 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 313 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 943 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 841 | 0.020 |
Why?
|
| Acute Disease | 2 | 2001 | 1108 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 486 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3436 | 0.020 |
Why?
|
| Estradiol | 1 | 2010 | 535 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 504 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3010 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1273 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 1297 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6312 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2706 | 0.020 |
Why?
|
| Germany | 1 | 2005 | 66 | 0.020 |
Why?
|
| Menopause | 1 | 2005 | 75 | 0.010 |
Why?
|
| Child | 1 | 2023 | 24463 | 0.010 |
Why?
|
| Adolescent | 1 | 2000 | 19333 | 0.010 |
Why?
|
| Ranitidine | 1 | 2001 | 31 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2001 | 167 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 2001 | 19 | 0.010 |
Why?
|
| Histamine | 1 | 2001 | 44 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2001 | 64 | 0.010 |
Why?
|
| Receptors, Oxytocin | 1 | 2001 | 19 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2001 | 121 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4429 | 0.010 |
Why?
|
| Ligation | 1 | 2001 | 135 | 0.010 |
Why?
|
| Duodenum | 1 | 2001 | 99 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1811 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 661 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 16296 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 12342 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2001 | 485 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 3288 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 3144 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 10275 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 7172 | 0.000 |
Why?
|